Amino-terminally truncated rantes as chemokine antagonists

Abstract

The present invention relates to amino-terminally truncated RANTES, lacking NH 2 -terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES (SEQ ID NO:2) and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.

1 . A method for the treatment of an inflammatory disease, HIV-infection, an angiogenic- or hematopoiesis-related disease, or a tumor, in a patient in need, comprising administering to the patient an effective amount of CD26/DPP IV.  
     
     
         2 . A method in accordance with  claim 1  for the treatment of an inflammatory disease, wherein the patient in need is one suffering from an inflammatory disease.  
     
     
         3 . A method in accordance with  claim 1  for the treatment of an HIV infection, wherein the patient in need is one suffering from an HIV infection.  
     
     
         4 . A method in accordance with  claim 1  for the treatment of an angiogenesis- or hematopoiesis-related disease, wherein the patient in need is one suffering from an angiogenesis- or hematopoiesis-related disease.  
     
     
         5 . A method in accordance with  claim 1  for the treatment of a tumor, wherein the patient in need is one suffering from a tumor.